Aptus Capital Advisors’s Merck MRK Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$25.5M Sell
175,259
-26,728
-13% -$3.69M 0.16% 113
2026
Q2
$26M Buy
201,987
+9,248
+5% +$1.08M 0.18% 109
2026
Q1
$23.2M Sell
192,739
-14,787
-7% -$1.71M 0.18% 103
2025
Q4
$21.8M Sell
207,526
-46,220
-18% -$4.34M 0.16% 120
2025
Q3
$21.3M Buy
253,746
+1,071
+0.4% +$88.2K 0.15% 127
2025
Q2
$20M Buy
252,675
+168,346
+200% +$13.4M 0.16% 124
2025
Q1
$7.57M Sell
84,329
-7,050
-8% -$658K 0.08% 217
2024
Q4
$9.15M Sell
91,379
-54,535
-37% -$5.62M 0.1% 178
2024
Q3
$16.6M Buy
145,914
+43,852
+43% +$5.21M 0.24% 96
2024
Q2
$12.6M Buy
102,062
+19,735
+24% +$2.54M 0.22% 95
2024
Q1
$10.9M Buy
82,327
+10,006
+14% +$1.23M 0.2% 98
2023
Q4
$7.88M Sell
72,321
-1,264
-2% -$131K 0.22% 99
2023
Q3
$7.58M Buy
73,585
+2,805
+4% +$302K 0.21% 99
2023
Q2
$8.17M Sell
70,780
-4,244
-6% -$482K 0.2% 100
2023
Q1
$7.99M Sell
75,024
-15,216
-17% -$1.64M 0.21% 96
2022
Q4
$10M Buy
90,240
+11,925
+15% +$1.22M 0.31% 69
2022
Q3
$6.76M Buy
78,315
+3,233
+4% +$289K 0.16% 85
2022
Q2
$6.86M Buy
75,082
+37,678
+101% +$3.34M 0.18% 80
2022
Q1
$3.08M Buy
37,404
+29,131
+352% +$2.3M 0.08% 148
2021
Q4
$638K Sell
8,273
-453
-5% -$36.1K 0.02% 271
2021
Q3
$660K Sell
8,726
-30,585
-78% -$2.33M 0.02% 270
2021
Q2
$3.06M Buy
39,311
+5,224
+15% +$389K 0.09% 113
2021
Q1
$2.63M Sell
34,087
-39
-0.1% -$3.02K 0.09% 111
2020
Q4
$2.8M Sell
34,126
-264
-0.8% -$21.2K 0.13% 101
2020
Q3
$2.86M Buy
34,390
+27,101
+372% +$2.22M 0.15% 86
2020
Q2
$563K Sell
7,289
-137
-2% -$10.8K 0.04% 184
2020
Q1
$571K Sell
7,426
-89
-1% -$7.33K 0.05% 163
2019
Q4
$683K Buy
7,515
+3,915
+109% +$337K 0.05% 217
2019
Q3
$303K Buy
3,600
+99
+3% +$8.32K 0.02% 322
2019
Q2
$293K Buy
3,501
+933
+36% +$74.9K 0.04% 282
2019
Q1
$213K Buy
+2,568
New +$201K 0.04% 292

Other funds holding MRK

Aptus Capital Advisors's MRK Position: Q3 2026 in Review

Aptus Capital Advisors reduced its Merck (MRK) stake by 13% in Q3 2026, selling an estimated $3.69M and leaving 175,259 shares worth $25.5M. The position accounts for 0.16% of the portfolio, ranked #113.

Aptus Capital Advisors first reported a position in MRK in Q1 2019 and has held it in 31 quarters since. The position peaked at $26M in Q2 2026. 3,977 funds tracked by Wall St. Rank hold MRK as of Q3 2026.

  • Aptus Capital Advisors held 175,259 shares of Merck worth $25.5M as of Q3 2026.
  • Aptus Capital Advisors sold 26,728 Merck shares in Q3 2026, an estimated $3.69M.
  • Merck made up 0.16% of Aptus Capital Advisors's portfolio in Q3 2026, its #113 holding.
  • Aptus Capital Advisors first reported a position in Merck in Q1 2019 and has held it in 31 quarters since.
  • Aptus Capital Advisors's Merck position peaked at $26M in Q2 2026.
  • 3,977 funds tracked by Wall St. Rank held Merck as of Q3 2026.

Based on Aptus Capital Advisors's 13F filing for Q3 2026, filed 13 Nov 2026.